Eisai Europe Limited

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

    London (ots/PRNewswire) - Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.

    A wide variety of abstracts on Eisai investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, mesothelioma, pancreatic cancer and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.

    "Eisai's commitment to oncology is clearly translating into the substantial growth of our pipeline," said Haruo Naito, President and CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families."

    The following Eisai abstracts are accepted for presentation at this year's ASCO meeting.

@@start.t1@@      Product              Abstract Details                                              Location
      MORAb-003          Exploratory Phase II Efficacy Study of          June 1, 2008
                                MORAb-003, a Monoclonal Antibody against
      (farletuzumab)  Folate Receptor Alpha, in                                4:30-4:45
                                Platinum-Sensitive Ovarian Cancer in First    p.m.
      Abstract No:      Relapse
      5500                                                                                          Location:
                                Oral Presentation                                            S406 (Vista
      E7080                 A phase I study of E7080 in patients with      May 31, 2008
                                advanced malignancies
      Abstract No:                                                                              8:00
      3526                                                                                          a.m.-12:00
                                Poster 3
                                Awarded a Foundation Merit Award                    W375E Lobby
      E7080                 Phase I dose escalation study and biomarker  May 31, 2008
                                analysis of E7080 in patients with advanced
      Abstract No:      solid tumors                                                    8:00
      3527                                                                                          a.m.-12:00
                                Poster 4                                                          p.m.
                                                                                                        W375E Lobby
      MORAb-003          A Phase I Study of MORAb-003, a Humanized      May 31, 2008
                                Monoclonal Antibody Against Folate Receptor
      (farletuzumab)  Alpha, in Advanced Epithelial Ovarian            2:00-6:00
                                Cancer                                                              p.m.
      Abstract No:
      5517                  Poster 7                                                          Location:
                                                                                                        S406 (Vista
      GCP II                Glutamate Carboxypeptidase II Inhibition in  May 31, 2008
      Inhibitor          Rat Models of Chemotherapy-induced
                                Peripheral Neurotoxicity                                 2:00-6:00
      Abstract No:                                                                              p.m.
      9558                  Poster 37A
                                                                                                        Location: S
                                                                                                        Hall A1
      E7820                 A phase I study of E7820 in combination         June 1, 2008
                                with cetuximab in patients (pts) with
      Abstract No:      advanced solid tumors                                      2:00-6:00
      3568                                                                                          p.m.
                                Poster 24G
                                                                                                        Location: S
                                                                                                        Hall A1
      MORAb-009          A Phase I Study of MORAb-009, a Monoclonal    June 1, 2008
                                Antibody against Mesothelin, in
      Abstract No:      Mesothelioma, Pancreatic, and Ovarian            2:00-6:00
      3578                  Cancer                                                              p.m.
                                Poster 27C                                                        Location: S
                                                                                                        Hall A1
      Eribulin            Phase II Study of Eribulin                              June 2, 2008
      Mesylate            Mesylate (E7389) in Patients
      (E7389)              with Locally Advanced or                                 2:00-6:00
      Abstract No:      Metastatic Breast Cancer                                 Location:
      1084                  Previously Treated with                                  S Hall A1
                                Anthracycline, Taxane, and
                                Capecitabine Therapy
                                Poster 38A
      Advanced Breast Oncologist and Patient Roles in                      June 2,
      Cancer                Assessing Current and Future                          2008
                                Treatment for Metastatic Breast                      2:00-6:00
      Abstract No:      Cancer: Results of an                                      p.m.
      1064                  Observational Linguistic study                        Location:
                                Poster 32B                                                        S Hall A1@@end@@

    Eisai began its oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the oncology market.

    In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology and supportive care.

    Eisai is committed to addressing the unmet medical needs of patients with cancer and to delivering novel treatment options that create hope.

    Note to Editors

    About Eisai Europe Ltd.

    Established in 1989, Eisai Europe Ltd. is the European pharmaceutical subsidiary of Eisai Co. Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai focuses its efforts in two main therapeutic areas; integrative neurology and integrative oncology/critical care. Eisai employs more than 9,500 people worldwide.

ots Originaltext: Eisai Europe Limited
Im Internet recherchierbar: http://www.presseportal.ch

For further information please contact: Andrew Day, Communications
Director, Eisai Europe Ltd, +44(0)208-600-1400, +44(0)7973-411-419

Weitere Meldungen: Eisai Europe Limited

Das könnte Sie auch interessieren: